Secukinumab Injection ( DrugBank: Secukinumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 160 | Congenital ichthyosis | 1 |
160. Congenital ichthyosis
Clinical trials : 42 / Drugs : 71 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04996485 (ClinicalTrials.gov) | March 1, 2021 | 21/7/2021 | Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children | Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children | Congenital Ichthyosis | Drug: Secukinumab Injection;Drug: Ustekinumab Injection;Drug: Dupilumab Injection;Other: Symptomatic therapy | National Medical Research Center for Children's Health, Russian Federation | NULL | Recruiting | 6 Months | 18 Years | All | 50 | Phase 4 | Russian Federation |